1. Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives
- Author
-
Mi Yan, Shutao Ma, Henrietta Venter, Ruixin Ma, Li Jia, Yan, Mi, Ma, Ruixin, Jia, Li, Venter, Henrietta, and Ma, Shutao
- Subjects
0301 basic medicine ,Models, Molecular ,Erythromycin-resistant bacteria ,synthesis ,Chemistry Techniques, Synthetic ,Microbial Sensitivity Tests ,Azithromycin ,01 natural sciences ,Microbiology ,03 medical and health sciences ,Structure-Activity Relationship ,antibacterial activity ,Bacterial Proteins ,Clarithromycin ,Drug Discovery ,Drug Resistance, Bacterial ,medicine ,Pharmacology ,Bacteria ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Broth microdilution ,General Medicine ,0104 chemical sciences ,Anti-Bacterial Agents ,030104 developmental biology ,3-O-Descladinosylazithromycin ,Antibacterial activity ,medicine.drug ,Nuclear chemistry - Abstract
Novel series of novel 3- O -arylalkylcarbamoyl descladinosylazithromycin derivatives with the 2′- O -acetyl and 11,12-cyclic carbonate groups, the 11,12-cyclic carbonate group and the 11- O -arylalkylcarbamoyl side chain, and 2′- O -arylalkylcarbamoyl descladinosylazithromycin with the 11,12-cyclic carbonate group were designed, synthesized and evaluated for their antibacterial activity using broth microdilution method. The results showed that the majority of the target compounds showed moderate to favorable activity against six kinds of susceptible strains and almost all of them displayed significantly improved activity compared with references against three erythromycin-resistant strains of S. pneumoniae B1 expressing the erm B gene, S. pneumoniae AB11 expressing the erm B and mef A genes, and S. pyogenes R1. In particular, compound 6h exhibited the most potent activity against susceptible B. subtilis ATCC9372 (0.5 μg/mL), penicillin-resistant S. epidermidis (0.125 μg/mL), and erythromycin-resistant S. pneumoniae B1 (1 μg/mL) and S. pneumoniae AB11 (1 μg/mL), which were 2-, 2-, 256-, 256-fold better activity than azithromycin, respectively. Additionally, compounds 6f (0.5 μg/mL) and 6g (0.25 μg/mL) were the most active against S. pneumoniae A22072, which were 8- and 16-fold better activity than azithromycin (4 μg/mL). As for erythromycin-resistant S. pyogenes R1, compound 5a presented the most excellent activity (8 μg/mL), showing 32- and 32-fold higher activity than azithromycin (256 μg/mL) and clarithromycin (256 μg/mL).
- Published
- 2016